Abstract
Here we report results from the Bipolar Exome (BipEx) collaboration analysis of whole exome sequencing of 13,933 individuals diagnosed with bipolar disorder (BD), matched with 14,422 controls. We find an excess of ultra-rare protein-truncating variants (PTVs) in BD patients among genes under strong evolutionary constraint, a signal evident in both major BD subtypes, bipolar 1 disorder (BD1) and bipolar 2 disorder (BD2). We also find an excess of ultra-rare PTVs within genes implicated from a recent schizophrenia exome meta-analysis (SCHEMA; 24,248 SCZ cases and 97,322 controls) and among binding targets of CHD8. Genes implicated from GWAS of BD, however, are not significantly enriched for ultra-rare PTVs. Combining BD gene-level results with SCHEMA, AKAP11 emerges as a definitive risk gene (ultra-rare PTVs seen in 33 cases and 13 controls, OR = 7.06, P = 2.83 × 10−9). At the protein level, AKAP-11 is known to interact with GSK3B, the hypothesized mechanism of action for lithium, one of the few treatments for BD. Overall, our results lend further support to the polygenic basis of BD and demonstrate a role for rare coding variation as a significant risk factor in BD onset.
Competing Interest Statement
B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen. D.S.P. is an employee of Genomics plc. All the analyses reported in this paper were performed as part of D.S.P.'s previous employment at the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.. C-Y.C. is an employee of Biogen. F.D. is an employee of Sheppard Pratt. A.L. and E.A.S. are now employees of Regeneron. All other authors declare no competing interests.
Funding Statement
This study was supported by generous support from the Stanley Family Foundation, Kent and Elizabeth Dauten, and The Dalio Foundation who have enabled us to rapidly expand our data generation collections with the goal of moving towards better treatments for bipolar disorder, schizophrenia, and other psychiatric disorders. BSC grant support was provided by the NIH, grant R01MH110437.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approvals and study consent forms from each of sample contributing organizations were sent to the Broad Institute before samples were sequenced and analyzed. Contributing organizations include: University of Aberdeen, Trinity college Dublin, University of Edinburgh, University College London, Cardiff University, University of Cambridge, Vrije Universitat, Amsterdam, University College of Los Angeles, Universitats Klinikum Frankfurt, Massachusetts General Hospital, Johns Hopkins University, Karolinska Institute, LifeGene Biorepository at Karolinska Institute, and Umea University. All ethical approvals are on file at the Massachusetts General Brigham (MGB), formerly Partners, IRB office amended to protocol #2014P001342, title: 'Molecular Profiling of Psychiatric Disease'.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Revised author list
Data Availability
We have provided data tables in the main text, Supplementary Methods. and in an exome results browser at https://bipex.broadinstitute.org. We display all of our results, from the variant and gene level in a browser available at https://bipex.broadinstitute.org. A detailed summary of phenotype curation, and QC, including additional plots is available at https://astheeggeggs.github.io/BipEx/. Whole Exome Sequence data generated under this study are hosted on and shared with the collaborating study groups via the controlled access Terra platform (https://app.terra.bio). The Terra environment, created by the Broad Institute, contains a rich system of workspace functionalities centered on data sharing and analysis. Requests for access to the controlled datasets are managed by data custodians at the Broad Institute and sent to sample contributing investigators for approval.
